Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring

NCT03790631 is registered in ClinicalTrials.gov with University of Geneva, Switzerland as lead sponsor.

NCT NCT03790631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03790631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring
Lead sponsor
University of Geneva, Switzerland
Phase
Observational
Overall status
Completed
Start date
January 14, 2019
Completion date
December 31, 2023
Enrollment
771 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

amoxicillin, beta-lactam antibiotics, cefepime, ceftazidime, efficacy, flucloxacillin, imipenem, meropenem, piperacillin, therapeutic drug monitoring, toxicity